You are here

Michael Ewing

  • Managing Director
(add to contacts)


Mike Ewing has spent over 25 years as a banker and principal investor in healthcare and the life sciences. 

Mike's experience includes domestic and cross-border (primarily Asia) M&A and equity capital raising, investment management, bankruptcy/reorganization, structured credit and capital markets advisory engagements. Mike also has significant operating experience from his active role in the management of portfolio company investments.

Mike has managed equity raises, structured debt issuance and M&A transactions with an aggregate value of in excess of $12 billion and advised on bankruptcy/reorganizations totaling over $2.8 billion in enterprise value in the managed care space. He has provided investment banking services as a sole proprietor and managed large deal teams at Dean Witter Reynolds and Houlihan Lokey Howard & Zukin. Mike has also been active as a principal investor, primarily in pharmaceutical services and specialty pharmaceuticals. 


Indiana University School of Law - JD - Law

Indiana University - BA - Mathematics, Economics

Registrations & Affiliations

FINRA - Series 79 Registered Investment Banking Representative

Industry Coverage

The increasing volume of gene therapy drugs under development will require greater manufacturing capacity and, in turn, greater utilization of CDMO capacity.  CDMOs may be able to increase penetration of their outsourced manufacturing services by providing services at the commercial stage in addition to the earlier stages of preclinical development and clinical trials.Read more

The well-managed, nonopportunistic use of outsourcing to support drug development and, in particular, the development and manufacturing functions, allows sponsor-innovators to take advantage of specialist expertise, resulting in higher compliance and productivity levels, shorter turnaround and set-up times, access to difficult-to-find expertise, shorter completion dates, and lower overall costs.Read more

In our third quarterly edition of our Institutional Industry Report on the Bio/Pharma Outsourced Services (BPOS) sector, we focus on the BPOS industry’s opportunities to support the development and manufacture of cannabinoid-based drugs. We hasten, however, to dampen any prurient interest in this topic by emphasizing that these drugs have no “mind-altering” effects and will not be available through the marijuana dispensaries popping up like flowers in the spring. Read more